Physician profile
Brigitte Grewe
NPI 1982345401
$622.24
in general payments reported to CMS, 2019-2025
14 companies · $622 in 2025
The $622 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $622.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $622.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $622.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $119.83 | 2025 | Veozah |
| Novo Nordisk INC | $77.94 | 2025 | Ozempic, Wegovy, Rybelsus |
| Bausch Health US, LLC | $70.77 | 2025 | Aplenzin, Wellbutrin |
| Lilly USA, LLC | $68.82 | 2025 | Zepbound, Mounjaro, Jardiance |
| Lundbeck LLC | $57.22 | 2025 | Rexulti |
| Exact Sciences Corporation | $51.96 | 2025 | The Cologuard Plus Collection Kit |
| Corium, LLC | $33.69 | 2025 | Azstarys |
| Paratek Pharmaceuticals, INC. | $30.44 | 2025 | Nuzyra |
| Merck Sharp & Dohme LLC | $24.96 | 2025 | Gardasil 9, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $21.64 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.16 | 2025 | Jardiance |
| Pfizer INC. | $16.41 | 2025 | |
| Abbvie INC. | $15.35 | 2025 | |
| Seqirus USA INC | $14.05 | 2025 | Fluad, Flucelvax |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brigitte Grewe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.